Featured Suppliers:

Ads by Google


 

Celgene Corporation


Suppliers

Total : 4 View more »

Celgene Corporation

Forest Hill, Maryland (Maryland) US

Medical research, commercial, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)...

TEL: 4104203631   
http://www.celgene.com

Locations:

San Diego, California USA

Company location:

 

News and Blogs

Total : 19 View more »

Celgene and Innate Collaborate on Trial Combining Their Multiple Myeloma Therapies

www.genengnews.com | Nov 18, 2009

Celgene and Innate Pharma agreed to work together to carry out a Phase II trial evaluating a combination of their treatments for multiple myeloma. Celgene’s Revlimid® and

http://www.genengnews.com/news/bnitem.aspx?name=68851356

Celgene Exercises Option To Drug Discovery Collaboration With PTC - Pharmaceutical Business Review

www.pharmaceutical-business-review.com | Sep 2, 2009

PTC Therapeutics (PTC) has reported that Celgene has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMST (Gene Expression Modulation by Small-molecules) technology.

http://www.pharmaceutical-business-review.com/news/celgene_exercises_option_to_drug_discovery_collaboration_with_ptc_090902

Celgene: Buy on a Pullback

seekingalpha.com | Nov 4, 2009

Ockham Research submits: So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008.

http://seekingalpha.com/article/171182-celgene-buy-on-a-pullback?source=feed

Celgene earnings rise in quarter

www.marketwatch.com | Oct 22, 2009

NEW YORK (MarketWatch) -- Celgene Corp. said Thursday that third-quarter earnings were $217 million, or 46 cents a share, compared to $137 million, or 29 cents a share, in the year-ago period. Celgene's adjusted earnings were 56 cents a share. Revenue was $695 million compared to $592 million.

http://www.marketwatch.com/story/celgene-earnings-rise-in-quarter-2009-10-22?siteid=rss

 

Research and Markets: Demand-Driven Forecasting: a Structured Approach to Forecasting - Zibb.com

Research and Markets (http://www.researchandmarkets.com/research/a97ba1/demanddriven_fore) has announced the addition of John Wiley and Sons Ltd's new report "Demand-Driven Forecasting: A Structured Approach to Forecasting" to their offering.

This is a practitioner based book that provides readers with real proven processes, methodologies, and performance metrics that can be applied immediately with significant improvement in forecast accuracy. It will be filled with real life examples and case studies to illustrate both best-in-class approaches as well as initial start-up approaches.

The tentative contents is:

Demystifying Forecasting: Myths versus Reality; Performing a Strategic Value Assessments; What Is Forecast Value Added; Practical Applications and Methods in Forecasting; Tool Box Approach to Forecasting; Demand-Driven Consensus Forecasting; Performance Metrics; Cultural barriers in Forecasting.

Praise for Demand-Driven Forecasting

A Structured Approach to Forecasting

"There are authors of advanced forecasting books who take an academic approach to explaining forecast modeling that focuses on the construction of arcane algorithms and mathematical proof that are not very useful for forecasting practitioners. Then, there are other authors who take a general approach to explaining demand planning, but gloss over technical content required of modern forecasters. Neither of these approaches is well-suited for helping business forecasters critically identify the best demand data sources, effectively apply appropriate statistical forecasting methods, and properly design efficient demand planning processes. In Demand-Driven Forecasting, Chase fills this void in the literature and provides the reader with concise explanations for advanced statistical methods and credible business advice for improving ways to predict demand for products and services. Whether you are an experienced professional forecasting manager, or a novice forecast analyst, you will find this book a valuable resource for your professional development." --Daniel Kiely, Senior Manager, Epidemiology, Forecasting & Analytics, Celgene Corporation

"Charlie Chase has given forecasters a clear, responsible approach for ending the timeless tug of war between the need for 'forecast rigor' and the call for greater inclusion of 'client judgment.' By advancing the use of 'domain knowledge' and hypothesis testing to enrich base-case forecasts, he has empowered professional forecasters to step up and impact their companies' business results favorably and profoundly, all the while enhancing the organizational stature of forecasters broadly." --Bob Woodard, Vice President, Global Consumer and Customer Insights, Campbell Soup Company

Key Topics Covered:

Foreword. Preface. Acknowledgments. Chapter 1: Demystifying Forecasting: Myths versus Reality. Chapter 2: What Is Demand-Driven Forecasting? Chapter 3: Overview of Forecasting Methods. Chapter 4: Measuring Forecast Performance. Chapter 5: Quantitative Forecasting methods using time series data Chapter 6: Quantitative Forecasting Methods Using Causal Data. Chapter 7: Weighted Combined Forecasting Methods. Chapter 8: Sensing, Shaping, and Linking Demand to Supply: A Case Study Using MTCA. Chapter 9: Strategic Value Assessment: Assessing the Readiness of Your Demand Forecasting Process. Index.

For more information visit http://www.researchandmarkets.com/research/a97ba1/demanddriven_fore

SOURCE: Research and Markets

Research and Markets 
Laura Wood, Senior Manager, 
press@researchandmarkets.com 
U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

Read more...

Tags: academic   book   business   consumer   forecasts   index   investment opinion   president   products   war  

Companies: John Wiley & Sons, Inc. (JW/A)

 

Critical Alerts For Visa, Schlumberger, Celgene, Illumina, and American Water Works Released By

Seven Summits Research issues PriceWatch Alerts for V, SLB, CELG, ILMN, and AWK.

Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/111809B (Note: You may have to copy this link into your browser then press the [ENTER] key.)

Today's PriceWatch Alerts cover the following stocks: Visa, Inc. (NYSE: V), Schlumberger Limited (NYSE: SLB), Celgene Corporation (Nasdaq: CELG), Illumina Inc. (Nasdaq: ILMN), and American Water Works Company, Inc. (NYSE: AWK).

In today's unsure markets these brief PriceWatch Alerts contain concise detailed strategies for each covered stock and include position protection tactics designed to potentially defend investors from unexpected market shifts. While other market reports only provide stock news and opinion, we offer strategies that position investments against uncertainty and increase chances of making a profit, even if a stock goes down.

"Our PriceWatch Alerts go beyond other market reports. Along with a brief concise overview, each PriceWatch Alert provides useful strategies, which ensure potential investments are protected with basic hedging techniques," says Reid Stratton, Seven Summits Senior Analyst. "These brief company reports contain information that can benefit expert and novice investors who want to stay ahead of the market."

For essential information on stocks poised to move go to:

http://www.iotogo.com/s/111809B for Seven Summits Strategic Investments' PriceWatch Alerts.

Seven Summits Investment Research is an independent investment research group, which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help our clients make the best possible investment decisions. For more information go to www.SevenSummitsInvestmentResearch.com . CRD# 137114

All stocks and options shown are examples only-- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security. Potential returns do not take into account your trade size, brokerage commissions or taxes--expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available from Catherine at 800-698-9101 or at http://www.cboe.com/Resources/Intro.aspx . Privacy policy available upon request.

SOURCE Seven Summits Investment Research

http://www.sevensummitsstrategicinvestments.com

Read more...

Tags: equity   investment   investment opinion   market   nasdaq   note   nyse   policy   profit   research   security   taxes   trade  

Companies: American Water Works Co., Inc. (AWK), Celgene Corp. (CELG), Illumina, Inc. (ILMN), Schlumberger Ltd. (SLB), Visa Inc (V)

 

Celgene (CELG) Trading With Very Positive 5 STARs S&P Rating - Zibb.com

Celgene (NasdaqNM: CELG) closed yesterday at $54.01. So far the stock has hit a 52-week low of $36.90 and 52-week high of $60.42. Celgene stock has been showing support around 52.91 and resistance in the 54.69 range. Technical indicators for the stock are Bullish and S&P gives CELG a very positive 5 STAR (out of 5) strong buy rating. CELG appears on the Investors Observer Momentum Plays list. For a hedged play on this stock, look at a Jan '10 55 covered call (LQH AK) for a net debit in the $51.36 area. That is also the break even stock price for this trade. This covered call has a 60 day duration, provides 4.91% downside protection and a 7.09% assigned return rate for a 43.11% annualized return rate (comparison purposes only). A lower cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the CELG Jan '11 25 Call (VCS AE) and selling the Jan '10 55 call (LQH AK) for a $27.25 debit. The trade has a 60 day life and would provide 3.26% downside protection and a 10.09% assigned return rate for a 61.00% annualized return rate (for comparison purposes only). Celgene does not pay dividends at this time.

ATU-Seven Summits Research Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock

Tags: dividends   research   S&P   trade  

Companies: Celgene Corp. (CELG)

 

More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented

Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID(R), VIDAZA(R), THALOMID(R), pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, 2009 in New Orleans, Louisiana.

Clinical and scientific abstracts will be presented in oral and poster sessions as an exchange of recent and updated scientific and clinical data and will report important new results in indications such as multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia and myelodysplastic syndromes.

For more information and for complete abstracts, please visit http://ash.confex.com/ash/2009/webprogram/start.html

About Celgene

Celgene Corporation, based in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements. The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports. Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

SOURCE: Celgene Corporation

Celgene Corporation 
David W. Gryska, 908-673-9059 
Senior Vice President and Chief Financial Officer 
or 
Brian P. Gill, 908-673-9530 
Vice President, Corporate Communications

Read more...

Tags: cancer   clinical   nasdaq   new jersey   products   research   science  

Companies: Celgene Corp. (CELG)

 

Web Sites

Total : 159 View more »

[video] 3 Stocks I Saw on TV (at TheStreet.com)

www.thestreet.com

Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Wachovia, Celgene and General Motors.

http://www.thestreet.com/_yahoo/video/strategysession/10419675.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA

Apria - resources - News

Jan 01, 2009 (Zacks Investment Research via COMTEX) -- Celgene Corp. (CELG) is a fully integrated biotechnology company focused on discovery, development and commercialization of drugs in the area of cancer and immune/inflammatory diseases.

http://www.apria.com/resources/1,2725,494-867778-3,00.html

GPC-Biotech

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration.

http://www.gpc-biotech.com/en/anticancer_programs/satraplatin/clinical_trials/

Free Historical Stock Price Data on Celgene Corp , Historical Stock Prices on Celgene Corp

Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering.

http://www.price-data.com/celg.cfm

Web Sites powered by Bing

Total : 223,000 View more »

Celgene Corporation—A Multinational Biopharmaceutical Company

www.celgene.com

Get information about the Celgene corporation, a multinational biopharmaceutical company committed to improving the lives of patients worldwide.

http://www.celgene.com/

Celgene - Wikipedia, the free encyclopedia

en.wikipedia.org

Celgene Corporation (NASDAQ: CELG) is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey ...

http://en.wikipedia.org/wiki/Celgene_Corporation

Celgene Corporation - Google Finance

www.google.com

Get the latest on Celgene Corporation including up to date news, high quality discussion groups and more on Google Finance.

http://www.google.com/finance?q=NASDAQ:CELG

Celgene Corporation—Locations

www.celgene.com

Search for Celgene Corporation locations by region. ... Celgene Summit Site (Corporate Headquarters) 86 Morris Avenue Summit, NJ 07901

http://www.celgene.com/about-celgene/celgene-locations.aspx